Sultan, Hussein
Kumai, Takumi
Nagato, Toshihiro
Wu, Juan
Salazar, Andres M.
Celis, Esteban http://orcid.org/0000-0001-8299-4480
Funding for this research was provided by:
National Cancer Institute (R01CA157303)
Georgia Research Alliance
Article History
Received: 24 July 2018
Accepted: 24 December 2018
First Online: 2 January 2019
Compliance with ethical standards
:
: Andres M. Salazar is President and CEO of Oncovir, Inc. and is developing poly-ICLC (Hiltonol ™) for the clinic. Esteban Celis is a consultant for Oncovir, Inc. and has filed patent applications based on the use of synthetic peptides and poly-IC combinatorial vaccines. The rights of the patent applications have been transferred to the Moffitt Cancer Center (Tampa, FL). Other authors declare no conflict of interest.
: C57BL/6 (WT-B6) and B6-Ly5.1 (CD45.1) mice were purchased from the National Cancer Institute (Wilmington, MA). TnTR1 TCR-transnuclear, pmel-1 and Trp1-KO mice were bred at the Georgia Cancer Center animal facility. All procedures performed in the experiments involving animals were in accordance with the ethical standards of the Augusta University Institutional Animal Care and Use Committee, where all the studies were conducted (Protocol No. 2013-0598, approved on 11/21/2016).
: The B16F10 murine melanoma cell line was obtained from the American Type Culture Collection.